Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

A COVID-19 infection can lead to clogged arteries which in turn increase chances of heart attacks in some patients, a new study suggests. The infection is associated with rapid growth of ...

Risk of long-term mortality is independently associated with eosinophil counts 5 to 7 days after onset in patients with acute myocardial infarction.

Exposure to TNF inhibitors was linked to a reduced risk for cardiovascular events among patients with AS; the impact of IL-17 inhibitors was less clear.

Oppenheimer’s 35th Annual Healthcare Life Sciences Conference Please contact your Oppenheimer representative to request a one-on-one meeting with management.

A new biological patch, designed from heart cells grown in the laboratory, could bring a glimmer of hope in the treatment of ...

BACKGROUND: The optimal coronary stenting technique for true left main bifurcation lesions is uncertain. EBC MAIN (European ...

Myocardial infarction remains one of the leading causes of mortality, which is usually complicated by the occurrence of ischemic ventricular arrhythmias, which in turn increase the risk of sudden ...

A new study by researchers at Karolinska Institutet and Södersjukhuset shows that advanced ultrasound imaging analyses cannot ...

A heart attack, or myocardial infarction, happens when blood flow to the heart becomes blocked. Classic symptoms include chest pain, shortness of breath, and heightened anxiety, but some people may ...

Selatogrel is under clinical development by Idorsia Pharmaceutical and currently in Phase III for Myocardial Infarction. According to GlobalData, Phase III drugs for Myocardial Infarction have a 65% ...

BI-765845 is under clinical development by Boehringer Ingelheim International and currently in Phase II for Myocardial Infarction. According to GlobalData, Phase II drugs for Myocardial Infarction ...